Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Shui-Pang Tam is active.

Publication


Featured researches published by Shui-Pang Tam.


PLOS ONE | 2008

Acute-Phase-HDL Remodeling by Heparan Sulfate Generates a Novel Lipoprotein with Exceptional Cholesterol Efflux Activity from Macrophages

Shui-Pang Tam; Robert Kisilevsky; John B. Ancsin

During episodes of acute-inflammation high-density lipoproteins (HDL), the carrier of so-called good cholesterol, experiences a major change in apolipoprotein composition and becomes acute-phase HDL (AP-HDL). This altered, but physiologically important, HDL has an increased binding affinity for macrophages that is dependent on cell surface heparan sulfate (HS). While exploring the properties of AP-HDL∶HS interactions we discovered that HS caused significant remodeling of AP-HDL. The physical nature of this change in structure and its potential importance for cholesterol efflux from cholesterol-loaded macrophages was therefore investigated. In the presence of heparin, or HS, AP-HDL solutions at pH 5.2 became turbid within minutes. Analysis by centrifugation and gel electrophoresis indicated that AP-HDL was remodeled generating novel lipid poor particles composed only of apolipoprotein AI, which we designate β2. This remodeling is dependent on pH, glycosaminoglycan type, is promoted by Ca2+ and is independent of protease or lipase activity. Compared to HDL and AP-HDL, remodeled AP-HDL (S-HDL-SAA), containing β2 particles, demonstrated a 3-fold greater cholesterol efflux activity from cholesterol-loaded macrophage. Because the identified conditions causing this change in AP-HDL structure and function can exist physiologically at the surface of the macrophage, or in its endosomes, we postulate that AP-HDL contains latent functionalities that become apparent and active when it associates with macrophage cell surface/endosomal HS. In this way initial steps in the reverse cholesterol transport pathway are focused at sites of injury to mobilize cholesterol from macrophages that are actively participating in the phagocytosis of damaged membranes rich in cholesterol. The mechanism may also be of relevance to aspects of atherogenesis.


Amyloid | 2006

The path of murine serum amyloid a through peritoneal macrophages

Sarah M. Kinkley; William Bagshaw; Shui-Pang Tam; Robert Kisilevsky

Serum amyloid A (SAA) is a family of proteins encoded by four related genes. Of the four, isoforms 1.1 and 2.1 are acute phase proteins synthesized by the liver. They become major components of the HDL plasma fraction during acute tissue injury and the HDL/SAA complex is readily taken up by macrophages. Herein we investigated the path SAA follows when presented to macrophages as HDL/SAA or in liposomes. Using antibodies specific to SAA and confocal microscopy, or EM autoradiography where only SAA is radio-labeled, we show that HDL/SAA is taken up rapidly by macrophages and within 30 min SAA, or fragments thereof, proceeds through the cytoplasm to the peri-nuclear region and then the nucleus. Within 45–60 min SAA, or fragments thereof, is found back in the cytoplasm and at the plasma membrane where it is subsequently extruded. The observation that SAA, or fragments thereof, traverse the nucleus is a novel finding and may implicate SAA in macrophage gene regulation. It also raises questions by what mechanism SAA enters and leaves the nucleus. We further investigated if both SAA isoforms traffic through the macrophage in a similar manner. Isoform differences were observed. Both isoforms bind well to the plasma membrane of macrophages at 4°C, but at 37°C only SAA2.1 is taken up by the cell in significant quantity, and is observed in the nucleus, suggesting that the two isoforms are handled differently and that they may have discrete physiological roles.


Pediatric Pathology & Molecular Medicine | 2002

Acute phase serum amyloid A, cholesterol metabolism, and cardiovascular disease.

Robert Kisilevsky; Shui-Pang Tam


Archive | 2007

Compositions and methods for treating atherosclerosis

Robert Kisilevsky; Shui-Pang Tam; John B. Ancsin; Zongchao Jia


Archive | 2004

Peptides enhancing ceh activity or inhibiting acat activity, pharmaceutical compositions comprising these peptides and their use in the treatment of atherosclerosis

Robert Kisilevsky; Shui-Pang Tam; John B. Ancsin; Zongchao Jia


Archive | 2008

Labeled Macrophages and Methods of Use Thereof

Robert Bender; Allan M. Green; Perry M. Kim; Robert Kisilevsky; Douglas S. Mcnair; Shui-Pang Tam


Archive | 2004

In Vivo Influence of Serum Amyloid a 2.1 and Its Active Domains on Macrophage Cholesterol Export

Robert Kisilevsky; Shui-Pang Tam


Archive | 2004

Influence of Murine Serum Amyloid a 2.1, and Its Active Domains, on Human Macrophage Cholesterol Export in Cell Culture

Robert Kisilevsky; Shui-Pang Tam


Archive | 2004

Compositions et methodes de traitement de l'atherosclerose

John B. Ancsin; Zongchao Jia; Robert Kisilevsky; Shui-Pang Tam


Archive | 2004

Peptides enhancing ceh activity or inhibiting acat activity for treating atherosclerosis

John B. Ancsin; Zongchao Jia; Robert Kisilevsky; Shui-Pang Tam

Collaboration


Dive into the Shui-Pang Tam's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

William Bagshaw

Kingston General Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge